Eighty percent of MG patients have antibody production against the nicotinic acetylcholine receptor (AchR) in the neuromuscular junction, and a smaller number of patients have antibodies against muscle-specific kinase (MusK) or lipoprotein-receptor-related protein 4 (LRP4). This evidence concerns the gene MUSK and myasthenia gravis.